Compositions for management of Helicobacter pylori infections
US10792295B2 · kind B2 · utility
4Cited by
0References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 6, 2018 |
| Grant date | Oct 6, 2020 |
| Priority date | — |
| Expiry date | Oct 20, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are compositions containing at least 10% w/w or above of 1-O-galloyl-β-D-glucose (β-glucogallin) which additionally comprising of about 10% w/w to greater than 60% w/w total mucic acid gallates including mucic acid 1,4-lactone 5-O-gallate, mucic acid 2-O-gallate, mucic acid 6-Methyl ester 2-O-gallate, mucic acid 1-Methyl ester 2-O-gallate and ellagic acid, and a probiotic bacteria Bacillus coagulans MTCC 5856, individually or in combination for inhibiting the growth and managing infections of Helicobacter pylori.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.